Pfenex Inc

Pfenex — Investor Presentation (March 2018)

22 slides from Pfenex's investor presentation, Mar 15, 2018

  1. Slide 1: Pfenex (NYSE American: PFNX)

    NYSE American: PFNX Exhibit 99.2

  2. Slide 2: Forward-looking statements

    This presentation, including the accompanying oral presentation (the “Presentation”), includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on current expectations, estimates and projections based on information currently avai

  3. Slide 3: Pfenex Overview

    Clinical stage development and licensing biotechnology company focused on leveraging its Pfenex Expression Technology® to improve protein therapies for unmet patient needs Advanced pipeline of therapeutic equivalents, vaccines, biologics and biosimilars Key pipeline products drive significant near t

  4. Slide 4: Pfenex Expression Technology Platform

    Pfenex Expression Technology® Platform based on Pseudomonas fluorescens Proprietary Platform 60+ partnerships, including 12 of 15 top pharma companies, resulting in multiple existing royalty-bearing partnerships plus broad wholly-owned portfolio Validated Scalable Therapeutic equivalents, vaccines,

  5. Slide 5: Proprietary Platform

    Proprietary Platform Pfenex Expression Technology® Platform based on Pseudomonas fluorescens Robust Analytics State of the art analytical capability ensures high quality & targeted process optimization 3 Advanced Strain Engineering 1 Accelerated Development 2 Integrated and highly automated developm

  6. Slide 6: Pipeline Highlights

    Products in Development Pipeline Highlights Existing USG THIRD-PARTY Anthrax Vaccine Contract 5 Years - $911MM3 $1.7B Reference drug 2017 Global sales2 $3.3B $4.5B $0.2B PF7081 Teriparatide (Forteo®) PF582 Ranibizumab (Lucentis®) PF529 Pegfilgrastim (Neulasta®) PF690 Pegaspargase (Oncaspar®) PF743 R

  7. Slide 7: Focused Execution for 2018

    Focused Execution for 2018 Focus on and deliver key programs 1 Selectively expand and maximize our Pfenex Expression Technology® based partnered portfolio 2 Drive development and commercial partnerships 3 Targeted and lean execution 4 Strong base for success Anticipated Key Milestones PF708 (teripar

  8. Slide 8: Strong Financial Position

    Strong Financial Position Financials Shares Outstanding 23.6 million as of December 31, 2017 Total Cash $57.7 million as of December 31, 2017 Runway Cash position that supports key 2018 milestones and >12 months runway

  9. Slide 9: Experienced Management

    Evert (Eef) Schimmelpennink (Aug 2017) CEO, President, Director and Secretary Patrick K. Lucy Chief Business Officer Hubert Chen Chief Medical & Scientific Officer Senior Management Board of Directors Experienced Management New and Established Leadership Aligned to Drive Growth John Taylor Dennis Fe

  10. Slide 10: Products in Development

    Products in Development

  11. Slide 11: Forteo (teriparatide) / PF708 bioequivalence

    Forteo® (teriparatide) rDNA protein and pen combination product Indicated for treatment of high fracture risk osteoporosis 2017 global sales of $1.7B of reference drug4 Pfenex achieved: bioequivalence in healthy subjects high titer protein production competitive cost of goods functionally equivalent

  12. Slide 12: Phase 3 osteoporosis trial nearing completion

    Phase 3 osteoporosis trial nearing completion N = 181, randomized 1:1 PF708 and Forteo® Primary endpoint immunogenicity Secondary endpoints pharmacokinetics, bone mineral density and bone turnover markers Phase 3 PK profiles show comparability between PF708 and Forteo® Complements Phase 1 bioequival

  13. Slide 13: PF708: Therapeutic Equivalent Candidate to Forteo

    Products in Development PF708: Therapeutic Equivalent Candidate to Forteo® Pfenex PF708 PF708 (teriparatide [rDNA] injection) Key upcoming program milestones: Primary endpoint of immunogenicity anticipated in Q2’18 505(b)(2) NDA filing expected Q3’18 Earliest projected commercial US launch Q3’19 Str

  14. Slide 14: Orange Book listed patents for Forteo

    Products in Development Orange Book listed patents for Forteo, teriparatide: Formulation Patents US6770623, US7144861, US7550434 (exp 08Dec18) Method of Treatment patents US6977077, US7351414, US7163684 (exp 19Aug19) Device Patent US7517334 (exp 25Mar25) The Pfenex teriparatide product launch is pla

  15. Slide 15: Jazz Pharmaceuticals/Pfenex Partnership

    Pfenex granted Jazz worldwide rights to develop and commercialize multiple Pfenex Expression Platform based hematology/oncology product candidates PF743 – recombinant crisantaspase PF745 – recombinant crisantaspase with half-life extension technology Key program highlights: Up to $224.5MM in upfront

  16. Slide 16: Px563L/RPA563: Next Generation Anthrax Vaccine Candidates

    Awarded BARDA contract in August 2015 Key program highlights: US Government funds up to $143.5MM of advanced development Potential procurement contract if within 10 years of FDA approval US administration has demonstrated strong support for development of medical countermeasures Current sole sourced

  17. Slide 17: Px563L/RPA563 vaccine candidate data

    Anthrax recombinant Protective Antigen (rPA) vaccine candidates: Demonstrated long term stability data from showing maintenance of high purity at 5°C at 40 months Phase 1a Day 70 analysis demonstrated that Px563L and RPA563 were well-tolerated and afforded immunogenicity protection with fewer doses

  18. Slide 18: PF582: Biosimilar to Lucentis

    Lucentis® (ranibizumab) main indication neovascular (wet) age-related macular degeneration Global Lucentis® market was $3.3 billion in 20177 Latest known composition of matter expected patent expiry: USA 2020; EU 20228 Phase 1/2 first-in-human study completed: Met primary objective of demonstrating

  19. Slide 19: PF529: Biosimilar Candidate to Neulasta

    Neulasta® (pegfilgrastim) is indicated for the prevention of febrile neutropenia in patients receiving cytotoxic chemotherapy Neulasta® global sales in 2017: $4.5 billion9 Production process developed and extensive analytical comparability to reference product completed Successfully completed a Bios

  20. Slide 20: Positioned well to drive value

    Proven success developing complex therapeutic proteins with Pfenex Expression Technology® platform Proven Platform Near-term Catalysts Runway PF708 immunogenicity study results Q2’18 and NDA submission Q3’18; Continuous advancement of development milestones in Jazz partnership programs; Potential Ph

  21. Slide 21: References

    References 1. Being developed via the 505(b)(2) pathway in the United States 2 Based on publicly available 2017 sales data for the third party branded pharmaceutical company 3 https://www.sec.gov/Archives/edgar/data/1367644/000136764416000084/form8kearningsq3q2016.htm 4 Eli Lilly Q4’17 and Full Year

  22. Slide 22: NYSE American: PFNX

    NYSE American: PFNX Corporate Presentation

Pfenex — Investor Presentation (March 2018) on 6ix